Omega Therapeutics ( (OMGA) ) has shared an announcement.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Michelle C. Werner has resigned from Omega Therapeutics’ Board of Directors and the Nominating and Corporate Governance Committee, effective immediately. The company has also received a non-binding proposal from Mirai Bio, Inc. to take over Omega’s rights and obligations under a collaboration agreement with Novo Nordisk and related entities. This proposal involves Mirai assuming $8 million of Omega’s debt, and the company’s Board has formed a special committee to evaluate the offer and explore strategic alternatives.
More about Omega Therapeutics
Omega Therapeutics operates within the biotechnology industry, focusing on the discovery and development of epigenetic and epigenomic controllers.
YTD Price Performance: -73.32%
Average Trading Volume: 321,751
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $44.48M
For a thorough assessment of OMGA stock, go to TipRanks’ Stock Analysis page.
Trending Articles
- Did Target’s (NYSE:TGT) Weirdly Hot Santa Help Sales?
- What Can Intel (NASDAQ:INTC) Do Against the Willow Processor?
- Amazon (NASDAQ:AMZN) Carries on With Grocery Store Plans
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
